Cross Timbers Royalty Trust
Change company Symbol lookup
Select an option...
CRT Cross Timbers Royalty Trust
ABBV Abbvie Inc
DD Dupont De Nemours Inc
NRXPW NRX Pharmaceuticals Equity Warrant Exp 24 May 2026 *W EXP 05/24/2026
SAH Sonic Automotive Inc
PCRX Pacira Biosciences Inc
ONFO Onfolio Holdings Inc
LSPRU Larkspur Health Acquisition Corp
BKKT Bakkt Holdings Inc
PDI PIMCO Dynamic Income Fund
Go

Energy : Oil, Gas & Consumable Fuels | Small Cap Blend
Company profile

Cross Timbers Royalty Trust (the Trust) is an express trust. The net profits interests are the principal asset of the Trust. The Trust receives net profits income from the net profit interests generally on the last business day of each month. The net profits interests comprise of approximately 90% net profits interests, which are carved from producing royalty and overriding royalty interest properties in Texas, Oklahoma and New Mexico, and 11.11% nonparticipating royalty interests in nonproducing properties located primarily in Texas and Oklahoma; and the approximately 75% net profits interests which are carved from working interests in four properties in Texas and three properties in Oklahoma. Its underlying royalties, underlying nonproducing royalties and underlying working interest properties are owned by XTO Energy. The underlying properties include approximately 2,900 producing properties in Texas, Oklahoma and New Mexico.

Closing Price
$22.12
Day's Change
0.00 (0.00%)
Bid
--
Ask
--
B/A Size
--
Day's High
--
Day's Low
--
Volume
(Heavy Day)
Volume:
54,473

10-day average volume:
37,670
54,473

Albireo to Participate in Guggenheim Nantucket Therapeutics Conference

8:00 am ET September 20, 2022 (Globe Newswire) Print

EQNX::TICKER_START (NASDAQ:ALBO), EQNX::TICKER_END Albireo Pharma, Inc. (Nasdaq: ALBO), a rare disease company developing novel bile acid modulators to treat pediatric and adult liver diseases, today announced participation in the Guggenheim Therapeutics Conference in Nantucket, MA, from September 27-29, 2022. Ron Cooper, President and Chief Executive Officer of Albireo, will be presenting on September 28, 2022, at 8:30 AM ET.

A replay of the webcast will be available on-demand on the Albireo Investors page: ir.albireopharma.com.

About Albireo

Albireo Pharma is a rare disease company focused on the development of novel bile acid modulators to treat pediatric and adult liver diseases. Albireo's lead product, Bylvay, was approved by the U.S. FDA as the first drug for the treatment of pruritus in all types of progressive familial intrahepatic cholestasis (PFIC), and it is also being developed to treat other rare pediatric cholestatic liver diseases with Phase 3 trials in Alagille syndrome (ALGS) and biliary atresia, as well as Open-label Extension (OLE) studies for PFIC and ALGS. In Europe, Bylvay is reimbursed for the treatment of PFIC in Germany, England, Wales & Northern Ireland, Scotland, Italy, and Belgium. The Company has also completed a Phase 1 clinical trial for A3907 to advance development in adult cholestatic liver disease, with IND-enabling studies progressing with A2342 for viral and cholestatic liver disease. Albireo was spun out from AstraZeneca in 2008 and is headquartered in Boston, Massachusetts, with its key operating subsidiary in Gothenburg, Sweden. For more information on Albireo, please visit www.albireopharma.com.

Media Contacts:

Colleen Alabiso, 857-356-3905, colleen.alabiso@albireopharma.com

Lance Buckley, 917-439-2241, lbuckley@lippetaylor.com

Investor Contact:

Hans Vitzthum, LifeSci Advisors, LLC., 617-430-7578

https://ml.globenewswire.com/media/8eef1fda-a775-421e-9f49-804f467ece7e/small/albireo-logo-jpg.jpg

https://ml.globenewswire.com/media/8eef1fda-a775-421e-9f49-804f467ece7e/small/albireo-logo-jpg.jpg

comtex tracking

COMTEX_414864939/2010/2022-09-20T08:00:02

Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2022. All rights reserved.